Breakthrough in Retinitis Pigmentosa Treatment: Nanoscope's Optogenetic Therapy Shows Durable Results

For individuals and families navigating the challenges of inherited retinal diseases (IRDs), particularly Retinitis Pigmentosa (RP), news of potential new treatments brings immense hope. Nanoscope Therapeutics has reported positive and durable results from its RESTORE Phase 2b/3 clinical trial and its long-term extension studies, REMAIN and EXTEND, for MCO-010, an optogenetic gene therapy designed to restore vision in patients with severe vision loss due to RP. This development is significant as it offers a mutation-agnostic approach, meaning it could potentially help a broader range of patients regardless of their specific genetic mutation causing RP.

Key Findings from Clinical Trials

Nanoscope Therapeutics' MCO-010 (sonpiretigene isteparvovec) is an ambient-light activatable optogenetic agent delivered via a single intravitreal injection. The therapy works by reprogramming healthy retinal cells, specifically bipolar cells, to become photosensitive, thereby bypassing damaged photoreceptors and enabling vision.

The RESTORE trial, a randomized, double-masked, sham-controlled study, enrolled 27 patients aged 18 and older with severe vision impairment from RP. Key findings include:

  • Significant Visual Acuity Improvement: The study met its primary endpoint, demonstrating a statistically significant improvement in Best Corrected Visual Acuity (BCVA) at week 52 in both MCO-010 dose groups compared to the sham group. Specifically, the high-dose group showed mean improvements of approximately 0.337 LogMAR at week 52 and 0.539 LogMAR at week 76, while the low-dose group also showed improvements.
  • Durable Efficacy: Improvements in visual function continued or increased beyond week 52, indicating a durable effect from a single intravitreal injection. The REMAIN study, a long-term extension of RESTORE, showed patients maintained an average BCVA gain of approximately 0.3 LogMAR (equivalent to three lines or 15 letters on a standard vision chart) through Week 152 (nearly three years).
  • Long-Term Safety and Tolerability: MCO-010 has demonstrated a favorable safety and tolerability profile over three years in the REMAIN study, with no serious ocular adverse events reported. Only one mild case of inflammation required topical steroids, and 14 of 15 treated patients required no ongoing inflammation management at the final follow-up.
  • Five-Year Safety Data: The EXTEND study, a five-year follow-up of participants from an earlier Phase 1/2a trial, confirmed that a single intravitreal injection of MCO-010 is safe and well-tolerated over five years, with no serious adverse effects or new safety signals.

What This Means for Patients and Families

These results offer substantial hope for the RP community. MCO-010 is designed to be a mutation-agnostic therapy, meaning it does not require genetic testing to determine patient eligibility, which broadens its potential applicability. The therapy is administered as a single, in-office intravitreal injection, avoiding the need for surgical intervention or repeat dosing. The sustained visual gains observed over several years are particularly encouraging, as patients with RP typically experience progressive vision loss.

Dr. Allen C. Ho, Director of Retina Research at Wills Eye Hospital and Chief Medical Advisor for Nanoscope, emphasized the significance, stating, "The ability to not just slow loss but restore visual function for several years represents a significant therapeutic advance."

Looking Ahead

Nanoscope Therapeutics has initiated a rolling Biologics License Application (BLA) submission to the FDA for MCO-010 for RP. The FDA has also granted MCO-010 both Orphan Drug and Fast Track designations for RP and Stargardt disease. If approved, MCO-010 could become the first FDA-approved optogenetic therapy for retinal diseases, potentially establishing a new standard of care for RP patients.